



---

**From:**

Saad Enouri, BVSc, MSc, PhD  
Research Associate, Canadian gFARAD  
Ontario Veterinary College  
senouri@uoguelph.ca  
Telephone: 519-824-4120 ext. 54984

---

|                              |  |
|------------------------------|--|
| <b>To:</b> [REDACTED]        | <b>Re:</b> Deccox® 6% Premix, Surmax™ 100 Premix |
| <b>Telephone:</b> [REDACTED] | <b>Case Id:</b> ON-112919-20806                  |
| <b>Fax:</b> [REDACTED]       | <b>Date of Response:</b> Dec 2, 2019 8:48:02 AM  |
| <b>Email:</b> [REDACTED]     |  |

---

**Case Information:**

**Date Submitted** Nov 29, 2019 2:11:11 PM  
**Species** Chickens/Broilers  
**Number of Animals** 15000  
**Location of Animals** Ontario  
**Reason for Use** Prophylaxis

**Drugs Administered**

| Drug Trade Name    | Generics        | Route       | Dose   | Diseases  |
|--------------------|-----------------|-------------|--|---|
| Deccox® 6% Premix  | • decoquinatate | Oral - Feed | 30 ppm (in feed)<br>Continuously for 23 days | • <b>Alimentary:</b><br>coccidiosis                                     |
| Surmax™ 100 Premix | • avilamycin    | Oral - Feed | 30 ppm (in feed)<br>Continuously for 23 days | • <b>Alimentary:</b><br>necrotic enteritis -<br>clostridium perfringens |

---

**Response and Recommendation:** 1 day

Decoquinatate is approved for inclusion in broiler chicken rations for the prevention of coccidiosis at 30 ppm to be fed from day-old to slaughter with a zero day withdrawal time. Avilamycin is approved for use in broiler chicken feeds for the prevention of necrotic enteritis at 15 to 30 ppm for 21 days with a zero day withdrawal time. The CMIB has now included this statement regarding avilamycin: "This livestock feed contains a medically important antibiotic. To reduce the development of antimicrobial resistance and maintain effectiveness, use this antibiotic prudently." Due to concerns regarding antimicrobial resistance, the Veterinary Drugs Directorate will no longer

approve antimicrobials for continuous use throughout the production cycle and they strongly discourage extended durations of therapy. As such, we suggest that extended treatments with avilamycin should be avoided whenever possible and if used beyond the approved 21 days, we recommend a withdrawal interval of at least 1 day. We are not aware of any interaction between these drugs that would require further extension of the withdrawal intervals. Therefore, we recommend following a withdrawal interval of at least 1 day for this combination.

Therefore, the Canadian gFARAD recommends a withdrawal interval of 1 day, which should be sufficient so that detectable residues are not found. Furthermore, this recommendation for residue avoidance does not address the risks of developing or transmitting antimicrobial resistance from treated animals to other animals or humans following the extralabel use of this antimicrobial. Because the Canadian gFARAD withdrawal recommendation is not an official withdrawal time and is based on data that has not been reviewed nor approved by the Veterinary Drugs Directorate or the Canadian Food Inspection Agency, responsibility for residue violations rests with the attending veterinarian.

To review this request in CgFARAD:

<https://farad.usask.ca/cgfarad/vet/viewRequest?id=20806&langen>